FSHD Global Announces Funding for miRecule 2nd generation therapy
FSHD Global Research Foundation in Sydney is excited to announce it has invested in miRecule’s second generation drug development program
July 28, 2026
News
Do you have an
FSHD topic or story
that you’d like to share?
We share ‘Progress’ our monthly newsletter with our community at large. If you have a story, questions or topics of interest you’d like read about, please contact us, as we’d love to hear from you.
Send an email to admin@fshdglobal.org.
ABC Radio National Breakfast
FSHD Global’s own Emma Weatherley was featured on an episode of Radio National Breakfast where she shared her personal story
July 21, 2026
FSHD Global collaboration with FSHD Canada enables advancement of Cyclo-Z, a First-in-Class Oral Muscle-Preserving Therapy
SEOUL, South Korea, July 06, 2026 (GLOBE NEWSWIRE) — NovMetaPharma Co., Ltd. (“NovMetaPharma” or “NMP”), a clinical-stage biopharmaceutical company that
July 7, 2026
Epicrispr positive trial and first use of AI twin
Epicrispr trial using Springbok AI twin shows positive clinical evidence of increased lean muscle, including results from an Australian site
June 27, 2026
New test for FSHD muscular dystrophy sends diagnosis skyrocketing
This method improves sensitivity and helps broaden the definition of genetic FSHD to more accurately correspond to clinical FSHD, allowing identification of those at risk in affected families and in large population studies.
June 19, 2026
New RNA therapeutic progressing to Phase III trials
Encouraging news from the Avidity/Novartis trial using targeted siRNA to suppress DUX4 in FSHD. The therapy, del-brax, is an investigational
June 15, 2026
Neuromuscular Disease Webinar
FSHD Global was pleased to join Muscular Dystrophy Queensland for a webinar covering the latest developments in FSHD research and
May 29, 2026
Whole-Body MRI in FSHD: Review and Future Directions
A review of the pioneering research that uses MRI scans and AI to enable clinical trials for FSH muscular dystrophy and other neuromuscular conditions.
May 27, 2026
A moment worth celebrating – the release of the interim report from Project Mercury
Project Mercury was established in 2023 to address critical challenges for clinical trials – ensuring safe and effective treatments reach patients quickly, equitably, and at scale.
May 25, 2026
Letter to the FSHD Community from Sarepta
26 March 2026 We welcome the announcement from Sarepta Therapeutics on early clinical data from its siRNA program targeting FSHD.
March 26, 2026